BROGGINI; Diego Fernando Domenico

Patent Applications and Registrations

Patent applications and USPTO patent grants for BROGGINI; Diego Fernando Domenico.The latest application filed is for "novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-- 1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazol- o[4,3-b][1,7]diazacyclotetradecin-5(6h)-one".

Company Profile

2.5.8

BROGGINI; Diego Fernando Domenico - Schaffhausen CH
Broggini; Diego Fernando Domenico - Zurich CH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Novel Synthetic Options Towards The Manufacture Of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-- 1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazol- O[4,3-b][1,7]diazacyclotetradecin-5(6h)-one App 20220144836 - CUNIERE; Nicolas ; et al.	2022-05-12
Compounds Grant 11,155,555 - Angibaud , et al. October 26, 2	2021-10-26
Pharmaceutical Compositions Comprising N-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl- )quinoxalin-6-yl]ethane-1,2-diamine App 20210169877 - BROGGINI; Diego Fernando Domenico	2021-06-10
Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-di- amine Grant 10,898,482 - Broggini January 26, 2	2021-01-26
New Compounds App 20200255401 - Kind Code	2020-08-13
Quinoxaline derivatives useful as FGFR kinase modulators Grant 10,421,747 - Vermeulen , et al. Sept	2019-09-24
Process for the preparation of histamine H3 receptor modulators Grant 10,323,002 - Broggini , et al.	2019-06-18
Quinoxaline Derivatives Useful As Fgfr Kinase Modulators App 20180186775 - VERMEULEN; Wim ; et al.	2018-07-05
Quinoxaline derivatives useful as FGFR kinase modulators Grant 9,902,714 - Vermeulen , et al. February 27, 2	2018-02-27
Pharmaceutical Compositions Comprising N-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl- )quinoxalin-6-yl]ethane-1,2-diamine App 20180021332 - BROGGINI; Diego Fernando Domenico	2018-01-25
Process For The Preparation Of Histamine H3 Receptor Modulators App 20180022704 - BROGGINI; Diego Fernando Domenico ; et al.	2018-01-25
Quinoxaline Derivatives Useful As Fgfr Kinase Modulators App 20170101396 - VERMEULEN; Wim ; et al.	2017-04-13
Process For The Preparation Of Histamine H3 Receptor Modulators App 20170057919 - BROGGINI; Diego Fernando Domenico ; et al.	2017-03-02

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.